Ketamine wafer could offer faster relief for depression and pain

NCT ID NCT07691372

First seen Jul 08, 2026 · Last updated Jul 09, 2026 · Updated 1 time

Summary

This study tests a new form of ketamine—a wafer that dissolves under the tongue—in healthy adults. Participants receive three different single doses (25 mg, 50 mg, and 75 mg) in a fixed order, with time between doses to clear the drug. Researchers measure how much ketamine enters the blood, how fast it is eliminated, and any side effects. The goal is to understand the drug's behavior in the body and its safety before testing in patients.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
Wafermine™ (ketamine sublingual wafer)
What this could lead to
If successful, this could lead to a new way to deliver ketamine for conditions like depression or pain, with faster absorption and fewer side effects than current methods.
What could go wrong
This is an early Phase 1 study in only 14 healthy people, so results may not apply to patients. Ketamine can cause side effects like dizziness, nausea, or dissociation.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEALTHY ADULT PARTICIPANTS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

Locations

  • Q-Pharm Pty Ltd.

    Brisbane, Queensland, 4006, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

More trials for these conditions

Other studies related to the condition(s) this trial covers.